Business Context and Reporting Period
This Form 8-K was filed by Propanc Health Group Corporation (also referred to as Propanc Biopharma, Inc.) on September 16, 2016, reporting events occurring on September 13, 2016. The filing details the entry into a material definitive agreement for additional financing.
Key Financial Metrics
- Debt Issuance: The Company entered into an Additional Issuance Agreement with Delafield Investments Limited.
- Loan Proceeds: $150,000 in cash received.
- Principal Amount: $165,000 (reflecting a 10% Original Issue Discount).
- Instrument Type: 5% Original Issue Discount Senior Secured Convertible Debenture.
- Maturity Date: September 13, 2017.
- Interest Rate: 5% per annum, payable quarterly in cash or stock at the Company's option.
- Default Interest Rate: 18% upon an event of default.
- Security: Secured by a first-priority security interest in all assets and property of the Company.
Material Changes and Terms
The filing reports the issuance of a new debenture under an existing Securities Purchase Agreement framework. Key terms include:
- Conversion Price: $0.03 per share (subject to adjustment).
- Volume Weighted Average Price (VWAP) Discount: If the VWAP is below the conversion price, the purchaser may convert at a 22.5% discount to the lowest trading price in the prior ten trading days.
- Default Conversion: Upon default, conversion is available at a 30% discount to the average VWAP of the prior three trading days.
- Beneficial Ownership Limitation: Conversion is capped at 4.99% of outstanding shares, extendable to 9.99% upon notice.
- Redemption: The Company may redeem the debenture at 125% of the outstanding amount after six months or upon registration of underlying shares.
- Warrant Exercise: The purchaser may apply principal amounts owed to exercise outstanding warrants.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking guidance, revenue projections, or management commentary on future operations. The primary risks and contingencies identified are:
- Dilution Risk: Significant potential dilution to existing shareholders due to the low conversion price ($0.03) and discount mechanisms.
- Default Risk: Accelerated conversion terms and higher interest rates (18%) apply in the event of default.
- Liquidity Constraints: The Company agreed to pay all reasonable out-of-pocket costs and legal fees incurred by the purchaser.
- Asset Security: All company assets are pledged as collateral until equity conditions are met.
Investor Verification Checklist
- Verify the current market price of the Common Stock relative to the $0.03 conversion price to assess immediate dilution potential.
- Confirm the total outstanding debt load including the $165,000 principal and any accrued interest from the Initial Debenture.
- Review the Company's cash position to determine ability to meet quarterly interest payments or potential redemption obligations.
- Check for any existing events of default that could trigger the 18% interest rate or 30% discount conversion.
- Examine the status of the registration statement for the New Underlying Shares, as this affects redemption rights.